Noven Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of advanced transdermal drug delivery technologies and prescription transdermal products. The company's prescription transdermal patches are used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), as well as in menopausal hormone therapy. Its products include Daytrana for the treatment of ADHD; Vivelle-Dot, a transdermal estrogen therapy product in the United States, which is marketed under the Estradot brand name outside the U.S.; and CombiPatch, a combination estrogen/progestin transdermal patch, which is marketed under the Estalis brand name outside the U.S. The company's menopausal hormone therapy products comprise Vivelle-Dot/Estradot, an advanced estrogen patch; Vivelle/Menorest/Femiest, an original estrogen patch; and CombiPatch/Estalis, a combination estrogen/progestin patch. It sells its products in the United States, Canada, Japan, and Europe. Noven Pharmaceuticals has collaboration agreements with Shire Pharmaceuticals Group plc; P&G Pharmaceuticals, Inc.; and Endo Pharmaceuticals, Inc. to develop a range of new patches. The company was founded in 1987 and is headquartered in Miami, Florida.